找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Imaging Tumor Response to Therapy; Massimo Aglietta,Daniele Regge Book 2012 Springer-Verlag Italia Srl 2012 Assessment of Response.Functio

[復制鏈接]
樓主: PLY
31#
發(fā)表于 2025-3-27 00:59:58 | 只看該作者
http://image.papertrans.cn/i/image/461693.jpg
32#
發(fā)表于 2025-3-27 02:05:54 | 只看該作者
Response to Treatment: The Role of Imagingsses for some forms of cancer—resulting in a 1% annual decline in mortality from all cancers in the USA since 1990—each year, about 7 million people worldwide and 600,000 in the USA continue to die from this disease [1].
33#
發(fā)表于 2025-3-27 08:12:10 | 只看該作者
Surrogate Endpoints of Clinical Benefit and, of course, a high priority for patients and society. Similar to the HIV/AIDS community, there have been numerous efforts to accelerate approvals of new drugs but also to shorten the times required in their development and marketing, with positive as well as negative consequences.
34#
發(fā)表于 2025-3-27 11:39:13 | 只看該作者
Renal Canceross, pyrexia, neuromyopathy, anemia, polycythemia, amyloidosis, elevated erythrocyte sedimentation rate, and abnormal liver function) are found in approximately 20–30% of patients with RCC and about 20–30% of all RCC patients have metastatic disease.
35#
發(fā)表于 2025-3-27 16:00:52 | 只看該作者
Hepatocellular Carcinomaiated with liver cirrhosis and chronic infection/chronic hepatitis from viral B and C hepatitis but toxic/metabolic diseases (alcohol abuse, hemochromatosis, and nonalcoholic steatohepatitis associated with obesity and diabetes) seem to be closely linked to a higher risk of developing HCC [3–5].
36#
發(fā)表于 2025-3-27 18:27:44 | 只看該作者
37#
發(fā)表于 2025-3-28 00:04:23 | 只看該作者
Book 2012 criteria in solid tumors) have provided means to objectively measure tumor response in clinical trials with imaging. These guidelines have been rapidly adopted in clinical practice to monitor patient treatment and for therapy planning. However, relying only on anatomical information is not always s
38#
發(fā)表于 2025-3-28 05:08:04 | 只看該作者
39#
發(fā)表于 2025-3-28 06:20:23 | 只看該作者
Pancreatic Cancerine therapy and as the reference treatment arm for clinical trials in this patient population [2, 3]. However, its anti-tumoral activity is disappointing because the response rate is around 10%, median survival about 6 months, and 1-year OS around 20%.
40#
發(fā)表于 2025-3-28 10:32:11 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2026-1-23 03:25
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
连江县| 绥宁县| 景谷| 文安县| 房山区| 乐陵市| 特克斯县| 潞城市| 陆良县| 荔波县| 松溪县| 上栗县| 盐津县| 西华县| 辽阳市| 英德市| 芷江| 遂平县| 大同市| 博野县| 襄樊市| 文水县| 白城市| 徐汇区| 陆丰市| 莎车县| 靖宇县| 晋江市| 依安县| 高密市| 阳朔县| 澄城县| 克拉玛依市| 新巴尔虎左旗| 神池县| 孙吴县| 册亨县| 金昌市| 克山县| 宁晋县| 都安|